Positive Results from Moderna Vaccine Trials Reported

The vaccine developed by Moderna against the novel coronavirus has successfully generated an immune response against SARS-CoV-2 during trial phases. This information is reported by Armenpress based on details from the company’s website.

In the clinical trial phases, 45 healthy individuals aged between 18 and 55 received two vaccinations 28 days apart, with dosages of 25 mcg, 100 mcg, and 250 mcg. Results obtained from participants of the initial dosage confirmed that those who received two vaccinations exhibited rapid and strong immune responses against SARS-CoV-2.

mRNA-1273 is generally considered safe, and no serious side effects have been reported within a 57-day monitoring period. Most side effects were transient and mild. After the second vaccination with the 100 mcg dosage, the most common side effects reported were fatigue (80%), chills (80%), headache (60%), and muscle pain (53%), all of which were transient and mild.

The most frequently reported adverse effect among those receiving the 100 mcg dosage was pain at the injection site (100%). More significant adverse effects were observed among participants who received the 250 mcg dosage, with three out of the 14 participants (21%) reporting more severe manifestations.